Agalimmune Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5.85M

Agalimmune General Information

Description

Developer of innovative anti-cancer immunotherapy technology designed to improve cancer treatments for benefit of patients. The company's lead compound, AGI-134, is a fully-synthetic alpha-Gal glycolipid immunotherapy for solid tumors, that recruits the patient's immune system to target autologous tumor antigens to attack the patient's own tumor cells.

Contact Information

Website
www.agalimmune.com
Formerly Known As
Alphamet
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Discovery Park House
  • Ramsgate Road
  • Sandwich CT13 9ND
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
BioLineRx
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Discovery Park House
  • Ramsgate Road
  • Sandwich CT13 9ND
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agalimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 23-Mar-2017 $5.85M Completed Generating Revenue
2. Early Stage VC 04-Jun-2014 Completed Generating Revenue
1. Early Stage VC 26-Nov-2013 Completed Generating Revenue
To view Agalimmune’s complete valuation and funding history, request access »

Agalimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of innovative anti-cancer immunotherapy technology designed to improve cancer treatments for benefit of patien
Biotechnology
Sandwich, United Kingdom
4 As of 2019

Abingdon, United Kingdom
 

Andover, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agalimmune Competitors (96)

One of Agalimmune’s 96 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Oncorus Formerly VC-backed Andover, MA
Achilles Therapeutics Formerly VC-backed London, United Kingdom
F-Star Therapeutics Formerly VC-backed Cambridge, United Kingdom
TScan Therapeutics Formerly VC-backed Waltham, MA
You’re viewing 5 of 96 competitors. Get the full list »

Agalimmune Patents

  • 24

    Total Documents Applications and Grants

  • Total Patents Families

  • 18

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Agalimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2015414272-A1 Glycolipid compounds and their uses in the treatment of tumours Active 11-Nov-2015
AU-2015414272-B2 Glycolipid compounds and their uses in the treatment of tumours Inactive 11-Nov-2015
CA-3004107-A1 Glycolipid compounds and their uses in the treatment of tumours Active 11-Nov-2015
CA-3004107-C Glycolipid compounds and their uses in the treatment of tumours Active 11-Nov-2015
EP-3374367-A1 Glycolipid compounds and their uses in the treatment of tumours Inactive 11-Nov-2015 C07H15/10
To view Agalimmune’s complete patent history, request access »

Agalimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Agalimmune Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Animatrix Founders Venture Capital Minority
Loxbridge Research Venture Capital Minority
To view Agalimmune’s complete investors history, request access »

Ready to get started?

Request a free trial

Agalimmune FAQs

  • When was Agalimmune founded?

    Agalimmune was founded in 2013.

  • Where is Agalimmune headquartered?

    Agalimmune is headquartered in Sandwich, United Kingdom.

  • What is the size of Agalimmune?

    Agalimmune has 4 total employees.

  • What industry is Agalimmune in?

    Agalimmune’s primary industry is Biotechnology.

  • Is Agalimmune a private or public company?

    Agalimmune is a Private company.

  • What is the current valuation of Agalimmune?

    The current valuation of Agalimmune is .

  • What is Agalimmune’s current revenue?

    The current revenue for Agalimmune is .

  • How much funding has Agalimmune raised over time?

    Agalimmune has raised $1.64M.

  • Who are Agalimmune’s investors?

    Animatrix Founders and Loxbridge Research have invested in Agalimmune.

  • Who are Agalimmune’s competitors?

    Adaptimmune Therapeutics, Oncorus, Achilles Therapeutics, F-Star Therapeutics, and TScan Therapeutics are some of the 96 competitors of Agalimmune.

  • When was Agalimmune acquired?

    Agalimmune was acquired on 23-Mar-2017.

  • Who acquired Agalimmune?

    Agalimmune was acquired by BioLineRx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »